
The Road from Scientic Breakthrough …
… to commercial Success.
Strategic, In Fair Partnership, with Vision, Strength, and Endurance.
Company
…is stony, but without alternative to ensure long-term competitiveness.
We have walked down this road ourselves and like to invite outstanding scientists and purpose-driven investors to join us in accompanying successful companies on their path to self-sufficiency. In doing so, we strengthen the competitiveness and resilience of our economy.
MARATHON puts emphasis on technical originality, quality, and scientific excellence.
Superior products for relevant unmet needs always have their value and price.
Cooperation between mind and money, rather than confrontation, and endurance to go all the way.
Welcome to MARATHON
What drives us?
Every productive society requires a successful economy as foundation for its services to the public. This is not only true with regard to financing education, healthcare, infrastructure, and administration, but above all it ensures a positive identification of the population with their commonwealth, in short, societal contentment.
Innovation cycles tend to render established large companies and their products regularly obsolete, as – in the pursuit of profit maximization – research and development budgets are systematically being cut back. In order to maintain long-term economic performance and diversity, therefore, it is necessary to found and empower new companies, to bring their products successfully to the commercial stage, allowing them to stay independent, without becoming themselves the merchandise.
Innovative products and services addressing hitherto unmet needs are typically developed by dedicated scientists and engineers.
A fair trade-off between mind („patents“) and money („investors“) forms the basis for a broad societal participation in economic success.
Marathon is committed to this principle.
Board of Management
Dr. Andreas Kluge – Chairman of the Investment Committee and the Board of Directors
Physician and passionate natural scientist by training, founder and managing director of several successful companies in the pharmaceutical and technology sectors (including ABX advanced biochemical compounds, Radeberg; ABX-CRO advanced pharmaceutical services, Dresden; Telix Pharmaceuticals, Melbourne, Australia; PharmAI Discovery, Dresden). Early on he recognized the medically disruptive and commercial potential of molecular imaging and radiotherapy.
Matthias Untisz – LLM, Chief Financial Officer
Economist and commercial lawyer, founder and managing director of the management consultancy Untisz & Co., specializing in founding, financing, and product development. Lecturer in business administration, tax sciences, and entrepreneurship at Brandenburg University of Technology Cottbus (BTU). For more than 20 years, he has accompanied companies in all aspects of their life cycle (founding, financing, growth, crisis management, and restructuring).
Supervisory Board
Christian Andreas Fintelmann – Ass. iur., Chairman of the Supervisory Board
Lawyer and political scientist, sales manager, managing director, and supervisory board member of numerous radiopharmaceutical and technology companies internationally (ABX-CRO, Dresden; Tetrakit AB, Copenhagen, DK; Therakles AG, Zug, CH; PINAX Pharma, Bad Liebenwerda; PharmAI Discovery, Dresden). As sales manager at ABX, he developed the market segment for radiopharmaceutical precursors de novo from 100 k € to over 100 million € annually within 15 years and was responsible for the successful commercialization of PSMA-617 from DKFZ (German Cancer Research Center, Heidelberg), which today generates more than 2.0 billion € in sales as Pluvicto®.